Oncology X Insights: CAR T Evaluation: Items to Consider

October 3, 2023

See the latest entry from the Oncology X Insights report, CAR T Evaluation: Items to Consider, by oncology expert, Simone Ndujiuba, PharmD, BCOP. This installment provides a brief summary of items to contemplate when evaluating CAR T products. Considerations include administrative burden, product availability, clinical trial outcomes, and more. You can read the full article here.